Literature DB >> 7862905

Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine.

K M Lawrence1, C L Katona, M T Abou-Saleh, M M Robertson, B L Nairac, D R Edwards, T Lock, R A Burns, D A Harrison, R W Horton.   

Abstract

Platelet [3H] paroxetine binding was measured in 73 depressed patients and in 64 healthy volunteers. No differences were found in Bmax or Kd either overall, or when the 61 depressed subjects who had never received psychotropic drugs were analysed separately. Within the depressed group, no differences in Bmax or Kd were found between subgroups divided on the basis of endogenicity, suicidal thoughts or severity of depression. None of the subgroups differed significantly from controls. Forty of the depressed subjects were retested after 6 weeks' treatment with fluoxetine (n = 22) or lofepramine (n = 18). Treatment was not associated with any change in Bmax but a similar and significant increase in Kd was noted following treatment with either antidepressant. Neither pre- nor post-treatment platelet binding parameters appeared to relate to clinical response to treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862905     DOI: 10.1007/bf02244781

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Validity of imipramine platelet binding sites as a biological marker of endogenous depression. A World Health Organization Collaborative Study.

Authors: 
Journal:  Pharmacopsychiatry       Date:  1990-05       Impact factor: 5.788

2.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

3.  3H-imipramine binding to previously frozen platelet membranes from depressed patients, before and after treatment.

Authors:  D Healy; A E Theodorou; A M Whitehouse; K M Lawrence; W White; H Wilton-Cox; S M Kerry; R W Horton; E S Paykel
Journal:  Br J Psychiatry       Date:  1990-08       Impact factor: 9.319

4.  Differentiation of two components of specific [3H]imipramine binding in rat brain.

Authors:  P D Hrdina
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

5.  Unaltered number of brain serotonin uptake sites in suicide victims.

Authors:  A Andersson; A Eriksson; J Marcusson
Journal:  J Psychopharmacol       Date:  1992-01       Impact factor: 4.153

Review 6.  Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets.

Authors:  J O Marcusson; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine.

Authors:  K M Lawrence; J Falkowski; R R Jacobson; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes.

Authors:  E T Mellerup; P Plenge; M Engelstoft
Journal:  Eur J Pharmacol       Date:  1983-12-23       Impact factor: 4.432

Review 9.  The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders.

Authors:  S M Stahl
Journal:  Arch Gen Psychiatry       Date:  1977-05

10.  Platelet 3H-paroxetine binding in depressed patients.

Authors:  H D'haenen; M De Waele; J E Leysen
Journal:  Psychiatry Res       Date:  1988-10       Impact factor: 3.222

View more
  2 in total

1.  Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls.

Authors:  K M Lawrence; F De Paermentier; S Lowther; M R Crompton; C L Katona; R W Horton
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

2.  Trazodone effects on [H]-paroxetine and alpha(2)-adrenoreceptors in platelets of patients with major depression.

Authors:  Donatella Marazziti; Giorgio Consoli; Francesca Golia; Stefano Baroni; Irene Masala; Marina Carlini; Mario Catena Dell'osso
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.